UNSPSC 51112205: Methotrexate/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN300. This VA Drug Class (AN300) classifies this compound as belonging to the group ANTINEOPLASTICS, ANTIMETABOLITES.

UNSPSC 51112205 Methotrexate/sodium chloride is a Commodity code covering this specific pharmaceutical formulation as procured by state and local health agencies. Recent state and local activity under this code centers on pharmacy benefit program design and direct-to-manufacturer prescription sourcing strategies rather than on procurement of the drug itself as a discrete product line. The Texas Health and Human Services Commission issued a Request for Information (RFI) in early April 2026 seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative that would establish direct relationships between state pharmacy programs and manufacturers, bypassing traditional pharmacy benefit managers and group purchasing organizations. The work being solicited includes vendor experience with direct contracting for self-insured employers and government health plans, flexible negotiated pricing models, and value-based or outcomes-based agreement structures. State health agencies and social services departments are the primary issuing bodies under this code, focused on optimizing pharmacy benefit delivery and cost management across employee and beneficiary populations.

Geographic activity is concentrated in Texas, where the HHS Commission's RFI represents current procurement interest in direct-to-manufacturer prescription programs. The April 2026 RFI did not specify award values, set-aside designations, or formal evaluation timelines, functioning as a preliminary market-intelligence tool to inform future formal procurement strategy before the state issues a structured RFP with binding financial and temporal parameters. Responses were due April 3, 2026. The lack of additional recent opportunities in the most-recent block suggests limited current activity under this specific commodity code across other jurisdictions; pursuit should focus on tracking the Texas HHS Commission's follow-up formal solicitation once the state completes its information-gathering phase.